PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30344692-7	2018	In conclusion, based on the conventional anti-heart failure therapy, the application of milrinone can reduce the serum IL-6, TNF-alpha and Cys-C levels and improve the cardiac functions of patients effectively.	Milrinone	88-97	tumor necrosis factor	Homo sapiens	125-134	
11969359-6	2002	Amrinone and milrinone, selective PDE3 inhibitors, suppressed TNF secretion to a lesser extent.	Milrinone	13-22	tumor necrosis factor	Homo sapiens	62-65	
10362376-9	1999	This phenomenon may be explained by the special abilities of agents, such as ACEI and milrinone, to inhibit the TNF-alpha production.	Milrinone	86-95	tumor necrosis factor	Homo sapiens	112-121	
8937731-13	1996	The PDE 3 inhibitor, milrinone produced a concentration-related inhibition of TNF-alpha release from monocytes which achieved statistical significance at 10(-5) M but inhibited LTB4 release from eosinophils and superoxide generation from macrophages only at the highest concentration (10(-3) M) examined.	Milrinone	21-30	tumor necrosis factor	Homo sapiens	78-87	
19426242-11	2009	Increased levels of tumor necrosis factor alpha during reperfusion were only abated by milrinone and levosimendan.	Milrinone	87-96	tumor necrosis factor	Homo sapiens	20-47	
21756812-12	2011	But the level of TNF-alpha (ng/L) was significantly lower at T(2), T(4), T(5) in milrinone group than that in control group (60 +- 5 vs 79 +- 7, 29 +- 6 vs 40 +- 8, 18 +- 5 vs 28 +- 7, all P < 0.05).	Milrinone	81-90	tumor necrosis factor	Homo sapiens	17-26